Twist Bioscience (NASDAQ:TWST) Shares Gap Down - Here's What Happened
Twist Bioscience (NASDAQ:TWST) shares gapped down before trading on Thursday, opening at $136.84 after closing at $142.39. Despite missing earnings expectations with a loss of $0.56 per share, the company exceeded revenue forecasts at $118.38 million. Analysts maintain a "Moderate Buy" consensus, though their average price target of $98.30 is significantly lower than the stock's current trading level.
Twist Bioscience stock hits 52-week high at 143.1 USD
Twist Bioscience (TWST) stock reached a new 52-week high of $143.10, currently trading at $143.35, reflecting a remarkable 438% return over the past year and a 349% gain year-to-date. Despite this surge and strong investor confidence, InvestingPro analysis suggests the stock may be overvalued. The company recently reported fiscal third-quarter 2026 revenue of $118.4 million, exceeding estimates, and continues its growth strategy despite skepticism from a short seller regarding its partnership with Anthropic.
Twist Bioscience Stock Hits 52-Week High - Here's Why
Twist Bioscience (NASDAQ: TWST) stock reached a new 52-week high after Anthropic selected the company as an independent evaluator for its AI models in protein design. Twist Bioscience is tasked with rapidly producing and testing AI-designed proteins to assess their binding capabilities, a crucial step in drug development. The company's stock shows strong technical indicators, including trading significantly above its moving averages and a recent golden cross formation.
Twist Bioscience Registers Invenra Share Resale Prospectus
Twist Bioscience (TWST) has filed a prospectus supplement to register the resale of shares issued to Invenra Inc. under a Stock Purchase Agreement from February 2026, supported by a legal opinion from Orrick, Herrington & Sutcliffe LLP. The company's stock currently holds a "Buy" rating from analysts with a $115 price target, though TipRanks' AI Analyst "Spark" rates TWST as "Neutral" due to weak financial performance despite strong technicals and recent positive corporate updates.
Twist Bioscience (NASDAQ: TWST) clears path for 35K-share resale
Twist Bioscience (NASDAQ: TWST) has filed a prospectus supplement to register for resale up to 35,114 shares of common stock held by Invenra Inc. These shares were issued under a Stock Purchase Agreement and may be sold over time through various brokerage or privately negotiated transactions. Twist Bioscience will not receive any proceeds from these sales, only covering registration-related expenses, and the filing also renews registration after a previous automatic shelf filing expired.
Twist Bioscience (TWST) Stock Draws Bulls After Guidance Hike And $300M Raise
Twist Bioscience (TWST) stock surged over 17% after raising its fiscal 2026 revenue guidance to $456M–$457M and projecting adjusted EBITDA breakeven for Q4, exceeding analyst expectations. The company also completed a $300M secondary offering to fund R&D and manufacturing expansion, further bolstering confidence despite a wider Q3 loss. Analysts from TD Cowen, Piper Sandler, and Baird all increased their price targets to $115, citing strong demand for AI-enabled drug discovery and a clear path to a cash-generative model.
TWST Looks 163.5% Overvalued on GF Value™
Twist Bioscience (NASDAQ: TWST) saw its shares surge over 15% after Anthropic selected it as an independent evaluator for AI-generated protein binders, highlighting growing interest in AI-leveraging biotech. Despite its innovative DNA synthesis platform, the company's GF Value™ suggests it is 163.5% overvalued, and it remains unprofitable with a high price-to-sales ratio. While institutional interest is mixed, insider selling indicates a cautious sentiment from management, advising investors to consider both growth prospects and significant valuation concerns.
Twist Bioscience (NASDAQ:TWST) Hits New 52-Week High - Should You Buy?
Twist Bioscience (NASDAQ:TWST) recently hit a new 52-week high, trading as high as $140.95. Despite positive analyst sentiment with a "Moderate Buy" consensus, the average price target of $98.30 is significantly below the current share price. The company reported a 23.2% year-over-year revenue increase to $118.38 million, beating estimates, but missed on EPS and is expected to remain unprofitable for the full year.
Why is Twist Bioscience stock surging today?
Twist Bioscience Corp (TWST) stock surged over 15% after Anthropic's research revealed its Claude AI models successfully designed protein binders, with Twist chosen to produce and validate these AI-designed proteins. This collaboration, formally disclosed in an 8-K filing, highlights Twist's central role in AI-driven drug discovery. The news, coupled with existing growth projections for AI-enabled drug discovery, pushed shares to a new 52-week high.
Form 8K Twist Bioscience Corp For: 19 August By Investing.com
This article reports on the filing of a Form 8K by Twist Bioscience Corp on August 19. It provides the title of the filing and notes that Investing.com is the source. The article itself is very brief, serving primarily as a notification of the SEC filing.
Twist Bioscience selected as evaluator for Anthropic AI protein design project
Twist Bioscience Corporation (NASDAQ:TWST) has been chosen as an independent evaluator for Anthropic's multi-arm protein design campaign, utilizing Anthropic's AI models, Claude Opus 4.8 and Mythos Preview. Twist Bioscience will rapidly produce and test the AI-designed proteins for binding properties. This announcement follows Twist Bioscience's recent fiscal third-quarter 2026 financial results, which showed a 23% increase in revenue to $118.4 million, though adjusted earnings reported a wider-than-expected loss of $0.56 per share.
Anthropic selects Twist Bioscience as independent evaluator for AI-designed protein testing
Anthropic has chosen Twist Bioscience to serve as an independent evaluator for testing AI-designed proteins. Twist Bioscience will rapidly produce and test these proteins at scale, following Anthropic's multi-arm protein design campaign using Claude Opus 4.8 and Mythos Preview. This collaboration aims to assess the binding capabilities of AI-designed proteins.
Twist Bioscience (NASDAQ: TWST) insider plans multimillion-dollar stock sale
An officer at Twist Bioscience (TWST), Patrick Finn, has filed a Rule 144 notice to sell up to 78,355 shares of common stock through Fidelity Brokerage Services LLC, valued at approximately $9.5 million. These shares were primarily acquired through restricted stock vesting and a stock option exercise, with the company reporting 62,707,424 shares outstanding as of August 18, 2026. This planned sale follows several prior sales by Finn in the last three months.
Twist Bioscience (TWST) Is Down 5.1% After Upsized Equity Raise And Guidance Hike Has The Bull Case Changed?
Twist Bioscience recently completed a $300 million stock offering and raised its full-year 2026 revenue guidance to $456-457 million, yet its stock fell 5.1%. While the capital raise strengthens its balance sheet, the company remains significantly loss-making, highlighting continued dilution risk. The article examines whether these developments alter the investment narrative, emphasizing the need for Twist Bioscience to convert top-line growth into profitability despite ongoing losses and dilution.
Bank of America Corp DE Grows Stake in Twist Bioscience Corporation $TWST
Bank of America Corp DE significantly increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 46.3% in the first quarter, now holding 584,261 shares valued at $27.8 million. Despite the increased institutional investment and a revenue beat, Twist Bioscience reported an adjusted loss that missed expectations, and analysts anticipate continued unprofitability for the year. The stock opened near its 52-week high, but company insiders have sold approximately $17.7 million in shares over the past 90 days.
T. Rowe Price Associates (TWST) discloses 3.63M-share Twist Bioscience position
T. Rowe Price Associates has reported a beneficial ownership of 3,634,470 shares of Twist Bioscience Corp. (TWST), representing a 5.8% stake in the company's common stock. The firm holds sole voting power over 3,520,536 shares and sole dispositive power over all 3,634,470 shares, as detailed in a Schedule 13G filing. T. Rowe Price Associates explicitly denies that the filing should be construed as an admission of beneficial ownership.
Twist Bioscience Corp (TWST) Stock Down 5.4% but Still Overvalued -- GF Score: 69/100
Twist Bioscience Corp (TWST) shares dropped by 5.4% to $118.57, yet the stock is considered 126.4% overvalued compared to its GF Value™ of $52.38. Despite a strong growth rank of 10/10, the company's profitability and valuation ranks are low, coupled with significant insider selling totaling $31.6 million, indicating caution for investors.
Twist Bioscience (TWST) director sells 2,240 shares to cover RSU tax
Twist Bioscience director Katryn Blake sold 2,240 shares of common stock on August 12, 2026, at $122.88 per share. This transaction was not a discretionary trade but was executed to cover tax liabilities arising from the vesting of Restricted Stock Units. Following the sale, Blake directly holds 17,208 shares of Twist Bioscience common stock.
Twist Bioscience (TWST): ARK Investment Management reports 4.55M-share, 7.31% stake
ARK Investment Management LLC and its founder Catherine D. Wood have reported a beneficial ownership of 4,549,803 shares of Twist Bioscience Corp (TWST) common stock, representing 7.31% of the company's class. The filing, a Schedule 13G/A, indicates that ARK has sole voting power over 4,254,988 shares and shared voting power over 58,669 shares, with sole dispositive power over all 4,549,803 shares. Catherine D. Wood holds shared voting power over 4,313,657 shares and shared dispositive power over 4,549,803 shares.
Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G
EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own these shares, with holdings representing 5% or less of the class. EdgePoint holds sole voting and dispositive power over 1,945,483 shares, and shared power over 576,152 shares.
Artisan Partners group (TWST) discloses 4.8M-share position in Twist Bioscience
Artisan Partners Asset Management Inc. and its affiliates have disclosed a beneficial ownership of 4,802,017 common shares, representing a 7.7% stake, in Twist Bioscience Corporation (TWST). This position is held on behalf of Artisan Partners Limited Partnership's discretionary clients, with shared voting power over 4,215,805 shares and shared dispositive power over all 4,802,017 shares. The disclosure was made via a SCHEDULE 13G/A SEC filing, indicating a passive investment approach.
Twist Bioscience stock hits 52-week high at 126.22 USD
Twist Bioscience stock reached a new 52-week high of $126.22, trading just 1% below this peak and marking a remarkable 440% surge from its 52-week low. The company also reported strong fiscal third-quarter 2026 revenues of $118.4 million, exceeding Wall Street estimates, although adjusted earnings showed a wider loss than anticipated. Despite the earnings miss, the consistent revenue growth and investor confidence have driven the stock's significant appreciation over the past year.
Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock
Twist Bioscience CEO Emily Leproust sold 113,318 shares of company stock for over $14.18 million, reducing her ownership by 12.16%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, with the stock trading near its one-year high. Despite missing EPS estimates, analysts maintain a "Moderate Buy" rating for TWST.
Twist Bioscience CEO Emily Leproust Executes Stock Option Exercise and Sells 113,318 Shares Under 10b5-1 Plan
Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), exercised stock options for 113,318 shares and subsequently sold them for a weighted average price of $125.1615 per share on August 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan established in May 2025. Following the sale, Leproust directly beneficially owns 818,938 shares of common stock and retains several other stock options.
Twist Bioscience (TWST) insider Leproust plans resale after option exercise
Twist Bioscience insider Emily M. Leproust has filed to resell up to 19,952 shares of common stock, valued at over $2.49 million, following a stock option exercise on August 12, 2026. This transaction is detailed in a Form 144 SEC filing, which also indicates previous stock sales by Leproust totaling more than 113,000 shares in the past three months. The company has 62,707,424 shares of common stock outstanding.
E. Ohman J or Asset Management AB Makes New Investment in Twist Bioscience Corporation $TWST
E. Ohman J or Asset Management AB has initiated a new position in Twist Bioscience Corporation, acquiring 8,287 shares valued at approximately $853,000. This investment comes as other major institutional investors, such as ARK Investment Management and Millennium Management, have also increased their holdings in TWST. Despite the stock opening at $123.12, above the average analyst target of $98.30, analysts maintain a "Moderate Buy" consensus rating for the company.
Twist Bioscience (TWST) stake of 3.5% reported by William Blair Investment Management
William Blair Investment Management, LLC has reported a 3.5% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,174,594 shares. This filing, a Schedule 13G/A, indicates that the investment firm has sole voting power over 1,975,454 shares and sole dispositive power over all 2,174,594 shares, classifying them as holding 5% or less of the common stock. The report was signed by Telmo Martins, Chief Compliance Officer, on August 11, 2026.
Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year High - Here's What Happened
Twist Bioscience (NASDAQ:TWST) reached a new 52-week high, trading as high as $121.50, despite its average analyst price target being below current trading levels. The company reported higher-than-expected revenue but a wider adjusted loss per share. While institutional investors have increased their holdings, company insiders have sold shares recently.
TWST shareholder (NASDAQ: TWST) files to sell 113,318 common shares
Emily M. Leproust, a shareholder of Twist Bioscience Corp (NASDAQ: TWST), has filed a Form 144 notice indicating her intent to sell 113,318 shares of common stock through Fidelity Brokerage Services LLC. The aggregate market value of this proposed sale is $14,183,056.89, with the transaction expected to occur on or after August 10, 2026, on NASDAQ. The filing also details several prior sales of TWST common stock by Ms. Leproust over the past three months.
Twist Bioscience TWST Jumps As Guidance, Targets And Cash Raise Align
Twist Bioscience (TWST) saw its stock jump after exceeding Q3 revenue expectations, raising its full-year 2026 guidance, and targeting adjusted EBITDA breakeven in Q4. Analyst firms like TD Cowen, Piper Sandler, and Baird increased their price targets to $115, citing strong demand from AI-enabled drug discovery and a clearer path to cash generation. The company also completed a $300M equity offering to fund R&D and expansion, balancing short-term dilution with long-term growth prospects.
Twist Bioscience Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:TWST) 2026-08-07
Twist Bioscience Corporation (NASDAQ: TWST) released its Q3 2026 earnings call presentation. The company reported an EPS of -$0.56, missing estimates by $0.38, while revenue reached $118.38M, surpassing expectations by $3.83M and representing a 23.24% year-over-year increase. This presentation was published in conjunction with their earnings call.
Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104
Analysts have increased their price target for Twist Bioscience Corporation (NASDAQ:TWST) to US$104 after the company's Q3 results showed revenue exceeding expectations, despite a statutory loss. The upgraded target reflects an improved revenue outlook, with forecasts predicting significant growth in 2027, even though the company is expected to remain loss-making. The revenue growth is anticipated to be in line with the broader industry.
Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Twist Bioscience Corporation (NASDAQ:TWST) has received a "Moderate Buy" consensus recommendation from brokerages, with eight buy ratings, one hold, and one sell among ten analysts. Despite an average 12-month price target of $98.30, below its recent opening price of $115.01, the company reported strong quarterly revenue of $118.38 million, up 23.2% year-over-year. However, it missed EPS estimates with an adjusted loss of $0.56 per share, and insiders have sold approximately $4.2 million worth of stock in the last quarter.
FMR LLC discloses 7.6% Twist Bioscience (TWST) holding in new ownership filing
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 7.6% in Twist Bioscience Corp (TWST) as of June 30, 2026. This translates to 4,703,044.11 shares, with FMR LLC holding sole dispositive power over all these shares and sole voting power over 4,701,268.00 shares. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same number of shares.
Earnings Update: Here's Why Analysts Just Lifted Their Twist Bioscience Corporation (NASDAQ:TWST) Price Target To US$104
Following Twist Bioscience Corporation's latest third-quarter results, analysts have updated their forecasts, lifting the consensus price target to US$104, a 13% increase. This comes despite the company still being loss-making, driven by an improved revenue outlook of US$539.2m for 2027. While revenue growth is expected to align with the wider industry, the upgraded price target suggests analysts see improved intrinsic value over time.
Twist Bioscience Nets ~$327 Million From $96-Per-Share Underwritten Stock Offering
Twist Bioscience has successfully completed an underwritten stock offering, selling 3,125,000 shares of common stock at $96.00 per share, with the underwriters fully exercising their option for an additional 468,750 shares. This offering is expected to generate approximately $327.1 million in net proceeds after accounting for discounts and expenses. The transaction, led by major financial institutions, is anticipated to finalize around August 6, 2026, and aims to raise capital and enhance the company's liquidity.
Twist Bioscience (TWST) Jumps As Guidance, Offering Reset The Trade
Twist Bioscience (TWST) saw its stock jump over 16% after reporting strong Q3 revenue, exceeding consensus, and raising its Q4 and FY26 revenue guidance. The company also announced an upsized $300M stock offering to fund R&D and manufacturing expansion, which, despite dilution, is seen as bolstering its balance sheet for future growth in synthetic DNA and AI drug discovery. Analysts like TD Cowen and Baird have raised price targets to $115, maintaining bullish ratings due to the positive outlook and strategic investments.
Twist Bioscience (NASDAQ: TWST) COO sells 2,888 shares for tax withholding
Patrick John Finn, President and COO of Twist Bioscience (NASDAQ: TWST), sold 2,888 shares of common stock on August 3, 2026, at an average price of $85.3212 per share. This transaction was a mandatory "sell to cover" to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and was not a discretionary trade. Following the sale, Finn directly holds 269,678 shares of the company's common stock.
Twist Bioscience TWST Rallies As Guidance And Capital Raise Reset The Bar
Twist Bioscience (TWST) experienced a significant stock rally of 16.14% following positive Q3 results, robust Q4 and FY26 guidance, and a $300M equity offering. The company beat revenue expectations, increased its full-year guidance, and is targeting adjusted EBITDA breakeven, signaling an improved path towards profitability. Analysts at TD Cowen and Baird have raised price targets to $115, endorsing the company's growth trajectory, especially in AI-enabled drug discovery, despite near-term dilution from the capital raise.
Twist Bioscience prices $300M stock offering at $96 per share
Twist Bioscience Corporation announced it has priced an underwritten public offering of 3,125,000 shares of common stock at $96.00 per share, aiming to raise $300.0 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase additional shares. The net proceeds from this offering are intended for research and development, manufacturing expansion, product offerings, and general corporate purposes.
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
Twist Bioscience Corporation announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at $96.00 per share, aiming to raise $300.0 million. The company plans to use the net proceeds for research and development investments, expanding manufacturing capacity and product offerings, and for general corporate purposes. The offering is expected to close on August 6, 2026, with an option for underwriters to purchase additional shares.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 4, 2026
Twist Bioscience Corporation announced that it will grant a total of 44,434 restricted stock units (RSUs) to 24 recently hired individuals as an inducement for their employment. These grants are made under Twist's Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, contingent on the employees' continued service.
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
Twist Bioscience Corporation announced a proposed underwritten public offering of $250.0 million of its common stock, with an option for underwriters to purchase an additional $37.5 million. The company plans to use the net proceeds, along with existing cash, for research and development investments, expanding manufacturing capacity and product offerings, working capital, and other general corporate purposes. Goldman Sachs & Co. LLC, William Blair, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers for the offering.
Twist Bioscience Corp stock hits 52-week high at 106.58 USD
Twist Bioscience Corp (TWST) reached a 52-week high of $106.58, with its stock currently trading at $103.80. The company has shown a robust 267.22% increase over the past year and recently reported fiscal third-quarter 2026 revenue of $118.4 million, exceeding expectations. Despite the strong revenue growth and 14 consecutive quarters of sequential revenue increase, the company reported a wider-than-anticipated adjusted earnings loss of $0.56 per share.
Twist Bioscience's 24 New Hires Set to Receive Stock Awards
Twist Bioscience (NASDAQ: TWST) announced it will grant a total of 44,434 restricted stock units (RSUs) to 24 new employees as an inducement to employment. These grants are made under the company's Amended and Restated Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, with specific vesting schedules tied to the employees' continued service.
Twist Bioscience Corporation Stock 12‑Month Price Target Raised to $109.67, Implies 20% Upside
Analysts have raised the 12-month average price target for Twist Bioscience Corporation (TWST) stock to $109.67, up from $104. This new target suggests a potential 20% upside from its July 31st closing price, with individual forecasts ranging from $85 to $120 per share. The consensus rating from 10 analysts remains a "Buy," with 9 Buys and 1 Hold.
Twist Bioscience Corp (TWST) (Q3 2026) Earnings Call Highlights: Record Revenue and AI-Driven ...
Twist Bioscience Corp (TWST) announced record revenue of $118.4 million in Q3 2026, marking its 14th consecutive quarter of growth, with AI-enabled drug discovery orders expected to achieve triple-digit growth. The company improved its gross margin to 52.8% and expects to reach adjusted EBITDA breakeven in Q4 2026, driven by strong therapeutics revenue and reduced manufacturing costs. Despite an adjusted EBITDA loss of $11.3 million due to one-time costs, Twist Bioscience raised its fiscal 2026 revenue guidance to $456-$457 million, anticipating continued momentum and leveraging its AI-driven approach.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation announced that it will grant 44,434 restricted stock units (RSUs) to 24 new hires as an inducement to their employment. These grants are made under Twist's Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, subject to continued employment.
Twist Bioscience Corp 2026: Revenue $118.38M, EPS ($0.56) — 10-Q Summary
Twist Bioscience Corp reported its 2026 quarterly results, showing a 23.2% increase in revenue to $118.38M compared to the prior year, driven by growth in DNA synthesis, protein products, and NGS applications. Despite increased revenue, the company's net loss widened to ($35.05M) with a diluted EPS of ($0.56). Business highlights include an expanding customer base, significant increases in genes shipped, improved year-to-date gross margin, and strategic activities like a license and equity commitment with Invenra.
TWIST BIOSCIENCE CORP : LEERINK PARTNERS RAISES TARGET PRICE $120.00 FROM $110.00
Leerink Partners has raised its target price for Twist Bioscience Corp (TWST.O) from $110.00 to $120.00. This indicates an increased positive outlook from the analytical firm regarding the company's future stock performance.
